WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics®, a clinical-stage biopharmaceutical company, today announced the closing of a $101 million Series E financing round. The proceeds of the round, led by Sarissa Capital and including Sun Pharmaceutical Industries Limited [Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715], ('Sun Pharma' and includes its subsidiaries and/or associate companies) and Polaris Partners, will support the development of Lyndra’s pipeline, including oral weekly risperidone (LYN-005), which is near completion of a pivotal phase 3 study..

马萨诸塞州沃特敦（商业新闻短讯）--临床阶段生物制药公司Lyndra Therapeutics®今天宣布结束1.01亿美元的E系列融资。由Sarissa Capital牵头，包括Sun Pharmaceutical Industries Limited[路透社：Sun.BO，彭博社：SUNP IN，NSE：SUNPHARMA，BSE：524715]，（“Sun Pharma”及其子公司和/或关联公司）和Polaris Partners，这一轮的收益将支持Lyndra渠道的发展，包括口服每周利培酮（LYN-005），即将完成关键的第三阶段研究。。

Lyndra’s investigational therapies are enabled by the company’s LYNX® drug delivery platform, which creates long-acting oral medicines that can be taken once weekly.

Lyndra的研究性治疗由该公司的LYNX®药物输送平台提供，该平台可以产生长效口服药物，每周服用一次。

“We appreciate the support our investors are providing as we complete our risperidone phase 3 trials and continue the development of our pipeline of oral weekly therapies through this round of financing,” said Jessica Ballinger, Lyndra Therapeutics’ President and CEO. “This investment validates the LYNX platform and moves us forward in our plans to bring our lead product candidate, oral weekly risperidone, through the regulatory pathway and to patients.”.

Lyndra Therapeutics总裁兼首席执行官杰西卡·巴林格（JessicaBallinger）表示：“我们感谢投资者提供的支持，因为我们完成了利培酮3期临床试验，并通过这轮融资继续开发我们的每周口服疗法管道。”。“这项投资验证了LYNX平台，并推动了我们的计划，通过监管途径将我们的主要候选产品利培酮口服每周给患者。”。

As part of the financing, Sun Pharma will receive an exclusive license to manufacture and market oral weekly risperidone (LYN-005), oral weekly dapagliflozin (LYN-045) and oral weekly aripiprazole (LYN-006) in six countries, including Brazil and India, pending further clinical development of these investigational candidates..

作为融资的一部分，Sun Pharma将获得独家许可，在包括巴西和印度在内的六个国家生产和销售口服利培酮（LYN-005），口服达格列净（LYN-045）和口服阿立哌唑（LYN-006），等待这些研究候选人的进一步临床开发。。

“This investment will provide Lyndra with the resources and leadership to achieve what we know is possible with the LYNX platform: a transformation of the relationship between people and their medicines,” said Amy Schulman, Lyndra Therapeutics co-founder, former CEO and Executive Chair of the Board.

Lyndra Therapeutics联合创始人、前首席执行官兼董事会执行主席艾米·舒尔曼（AmySchulman）表示：“这项投资将为Lyndra提供资源和领导力，以实现我们所知的LYNX平台可能实现的目标：改变人与药物之间的关系。”。

“This is an important step toward helping people adhere to their medication regimens and enabling them to better achieve their treatment goals.”.

“这是帮助人们坚持用药方案并使他们能够更好地实现治疗目标的重要一步。”。

Prior to the development of the LYNX technology, oral pills have been limited to ‘extended release’ formulations, which do not last for more than a day. Lyndra’s LYNX drug delivery platform is enabled by more than 50 patented innovations in design, engineering and materials science to achieve dramatically reduced dosing frequency.

在LYNX技术开发之前，口服药片仅限于“缓释”制剂，其持续时间不超过一天。Lyndra的LYNX药物输送平台通过设计、工程和材料科学领域的50多项专利创新得以实现，从而大大降低了给药频率。

The platform originated from the Bob Langer and Gio Traverso Laboratories at MIT, with which Lyndra has an exclusive technology license..

该平台源自麻省理工学院的Bob Langer和Gio Traverso实验室，Lyndra拥有专有技术许可证。。

The round follows a $20.3 million Series D financing led by Polaris Partners that was completed in June 2023.

本轮融资之前，Polaris Partners于2023年6月完成了2030万美元的D轮融资。

About Lyndra Therapeutics

关于Lyndra Therapeutics

Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra’s LYNX® drug delivery platform is one of the most significant advances in oral drug delivery in decades, creating medicines that last for a week or longer in an oral dosage form. Based on technology invented in the Bob Langer and Gio Traverso Laboratories at MIT, the LYNX platform has progressed rapidly since 2015 through preclinical and early human studies and achieved proof of concept of the platform and lead asset in a Phase 2 study.

Lyndra Therapeutics是一家临床阶段的生物制药公司，开创了长效口服疗法。Lyndra的LYNX®药物输送平台是几十年来口服药物输送领域最重大的进步之一，它创造了口服剂型持续一周或更长时间的药物。基于麻省理工学院Bob Langer和Gio Traverso实验室发明的技术，自2015年以来，LYNX平台通过临床前和早期人体研究取得了快速进展，并在第二阶段研究中实现了平台和领先资产的概念验证。

Lyndra’s initial focus is on developing therapies in psychiatry, cardiometabolic diseases and other conditions where current approaches to treatment fail to meet patients’ needs and expectations. Lyndra’s lead product candidate, oral weekly risperidone (LYN-005), is being developed for the treatment of people living with schizophrenia and bipolar 1 disorder.

Lyndra最初的重点是开发精神病学，心脏代谢疾病和其他目前的治疗方法无法满足患者需求和期望的疾病的治疗方法。Lyndra的主要候选产品口服利培酮（LYN-005）正在开发中，用于治疗精神分裂症和双相情感障碍患者。

Since the founding of Lyndra, the company has received product funding from the Bill & Melinda Gates Foundation, the NIH, AbbVie, and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA, and has a state-of-the-art GMP manufacturing facility in Lexington, MA. For more information, visit https://lyndra.com..

自Lyndra成立以来，该公司已获得比尔和梅琳达·盖茨基金会、NIH、AbbVie和Gilead Sciences，Inc.的产品资助。Lyndra总部位于马萨诸塞州沃特敦，并在马萨诸塞州列克星敦拥有最先进的GMP生产设施。有关更多信息，请访问https://lyndra.com..

About Sun Pharmaceutical Industries Limited

关于Sun Pharmaceutical Industries Limited

Sun Pharma is the world’s fourth largest specialty generics company with presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology and onco-dermatology and accounts for over 16% of company sales.

Sun Pharma是世界第四大专业仿制药公司，在专业、仿制药和消费保健产品领域拥有一席之地。它是印度最大的制药公司，也是美国和全球新兴市场领先的仿制药公司。Sun高速增长的全球专业产品组合涵盖皮肤科、眼科和肿瘤皮肤科的创新产品，占公司销售额的16%以上。

The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow Sun Pharma on “X” @SunPharma_Live..

该公司垂直整合的业务提供高质量的药物，受到100多个国家的医生和消费者的信任。其生产设施遍布六大洲。Sun Pharma为其来自50多个国家的多元文化员工队伍感到骄傲。欲了解更多信息，请访问www.sunpharma.com，并在“X”@sunpharma\u Live上关注Sun Pharma。。

About Sarissa Capital Management LP

关于Sarissa Capital Management LP

Sarissa Capital Management was founded by Alex Denner, Ph.D., in 2013 to capitalize on compelling opportunities for constructive shareholder activism within the healthcare sector. Sarissa's team of subject matter experts and philosophy of thoughtful engagement aims to create positive outcomes for investors, shareholders and patients by taking an owner-oriented approach to their investments.

Sarissa Capital Management由Alex Denner博士于2013年创立，旨在利用医疗保健领域内建设性股东积极行动的诱人机会。Sarissa的主题专家团队和深思熟虑的参与理念旨在通过采取以所有者为导向的投资方式，为投资者、股东和患者创造积极的成果。

Sarissa seeks to optimize healthcare companies so they can efficiently provide important medicines to society and increase the impact of medical innovation, while also generating value to shareholders..

Sarissa寻求优化医疗保健公司，使其能够有效地向社会提供重要药物，提高医疗创新的影响力，同时为股东创造价值。。